Variable-length haplotype construction for gene-gene interaction studies by Assawamakin, Anunchai et al.
ar
X
iv
:1
30
5.
43
33
v1
  [
q-
bio
.Q
M
]  1
9 M
ay
 20
13
Variable-Length Haplotype Construction for Gene-Gene Interaction
Studies
A. Assawamakin, N. Chaiyaratana, Member, IEEE, C. Limwongse, S. Sinsomros, P.-T. Yenchitsomanus
and P. Youngkong
Abstract— This paper presents a non-parametric classifica-
tion technique for identifying a candidate bi-allelic genetic
marker set that best describes disease susceptibility in gene-gene
interaction studies. The developed technique functions by cre-
ating a mapping between inferred haplotypes and case/control
status. The technique cycles through all possible marker
combination models generated from the available marker set
where the best interaction model is determined from prediction
accuracy and two auxiliary criteria including low-to-high order
haplotype propagation capability and model parsimony. Since
variable-length haplotypes are created during the best model
identification, the developed technique is referred to as a
variable-length haplotype construction for gene-gene interaction
(VarHAP) technique. VarHAP has been benchmarked against
a multifactor dimensionality reduction (MDR) program and
a haplotype interaction technique embedded in a FAMHAP
program in various two-locus interaction problems. The results
reveal that VarHAP is suitable for all interaction situations with
the presence of weak and strong linkage disequilibrium among
genetic markers.
Keywords: Case-control studies; Gene-gene interaction; Hap-
lotype; Linkage disequilibrium; Non-parametric classification
I. INTRODUCTION
Genetic epidemiology is a research field which aims
to identify genetic polymorphisms that involve in disease
susceptibility. Usual candidate polymorphisms include re-
striction fragment length polymorphisms (RFLPs), variable
numbers of tandem repeats (VNTRs) and single nucleotide
polymorphisms (SNPs). In recent years, SNPs are the most
common choices due to simplicity and cost reduction in
identification protocols. SNPs in diploid organisms are ex-
cellent bi-allelic genetic markers for various studies includ-
ing genetic association, gene-gene interaction and gene-
environment interaction. The availability of multiple SNPs
on the same gene can also lead to haplotype analysis where
genotypes of interest can be phased into pairs of haplotypes.
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Traditional techniques for identification of relationship
between a single SNP and disease susceptibility status in-
volve various univariate statistical tests including χ2 and
odds ratio tests [1], [2]. However, many complementary
computational techniques have been developed in the past
decade to handle problems that involve multiple SNPs. Hei-
dema et al. [3] have categorised these multi-locus techniques,
which are capable of identifying a candidate SNP set from
possible SNPs, into parametric and non-parametric methods.
Examples of parametric method cover logistic regression
techniques [4] and neural networks [5]. On the other hand,
examples of non-parametric method include a set associ-
ation approach [6], combinatorial techniques [7], [8], [9]
and recursive partitioning techniques [10], [11]. In some
of mentioned parametric [4], [5] and non-parametric [9]
methods, pattern recognition and classification approaches
have been successfully implemented as their core engines.
In addition to single and multiple SNP analysis, haplotype
analysis has also gained attention from genetic epidemiolo-
gists. Haplotypes provide a record of evolutionary history
more accurately than individual SNPs. Further, haplotypes
can capture the patterns of linkage disequilibrium (LD)—
a phenomenon where SNPs that are located in close prox-
imity tend to travel together—in genome more accurately.
Therefore, haplotypes may enable susceptibility gene identi-
fication in complex diseases more effectively than individual
SNPs [12]. In lieu of this evidence, haplotype analysis should
also be considered in addition to direct genotype analysis.
Many computational techniques use haplotypes, which are
inferred from multiple SNPs, as problem inputs. For instance,
Sham et al. [13] proposes a logistic regression technique
that produces a mapping model between haplotypes and
disease status while Becker et al. [14] combine haplotype
explanation probabilities of given genotypes from multiple
gene or unlinked region data into a scalar statistic for a
univariate test. Nonetheless, haplotypes have rarely been used
as inputs for non-parametric classifiers for genetic association
and interaction studies.
In this paper, a variable-length haplotype construction for
gene-gene interaction (VarHAP) technique is proposed. The
technique will involve non-parametric classification where
haplotypes inferred from multiple SNP data are the clas-
sifier inputs. The chosen architecture for non-parametric
classifier is the multifactor dimensionality reduction (MDR)
technique [9]. Similar to the original MDR technique, the
proposed technique would be able to identify appropriate
candidate SNPs from possible SNPs and can be used in case-
control genetic interaction studies. However, the technique
would also be able to handle the situation where disease sus-
ceptibility is detectable in different haplotype backgrounds.
The organisation of this paper is as follows. In section II,
a brief explanation of MDR and the techniques for inferring
haplotypes and obtaining haplotype explanation probability
is given. The proposed VarHAP technique is then described
in section III. The test data and their description is given in
section IV. Next, the results and discussions are described in
section V. Finally, the conclusions are drawn in section VI.
II. MDR, HAPLOTYPE INFERENCE AND HAPLOTYPE
EXPLANATION PROBABILITY
A. MDR
MDR is a classifier-based technique that is capable of
identifying the best genetic marker combination among pos-
sible markers for the separation between case and control
samples. Similar to other classification systems, a k-fold
cross-validation technique provides a means to determine
the classification accuracy of the candidate marker model.
Basically, the combined case and control samples are ran-
domly divided into k folds where k− 1 folds of samples are
used to construct a decision table for the classifier while the
remaining fold of samples is used to identify the prediction
capability of the constructed decision table. The decision
table construction and testing procedure is repeated k times.
Hence, the samples in each fold will always be utilised both
to construct and to test the decision table. The number of
cells in a decision table is given by Gnc where nc is the
number of candidate markers selected from possible markers
and G is the number of possible genotypes according to
the marker. For a SNP, which is a bi-allelic marker, G is
equal to three. During the decision table construction, each
cell in the table is filled with case and control samples
that have their genotype corresponds to the cell label. The
ratio between numbers of case and control samples will
provide the decision for each cell whether the corresponding
genotype is a disease-predisposing or protective genotype.
An example of decision table construction is illustrated in
Figure 1. The prediction accuracy of the decision table is
subsequently evaluated by counting the numbers of case and
control samples in the testing fold that their disease status can
be correctly identified using the constructed decision rules.
The process of decision table construction and evaluation
must be cycled through all or some of possible 2nm − 1
combinations where nm is the total number of available
markers in the study. The best genetic marker combination
is determined from three criteria: prediction accuracy, cross-
validation consistency and a sign test p-value. Each time that
a testing fold is used for prediction accuracy determination,
the accuracy of the interested marker combination model can
be compared with that from other models that also contain
the same number of markers. The model that consistently
ranks the first in comparison to other choices with the same
amount of markers would have high cross-validation con-
sistency. The non-parametric sign test p-value is calculated
Fig. 1
AN MDR DECISION TABLE WHICH IS CONSTRUCTED USING 1,200
CASE-CONTROL SAMPLES. THE GENOTYPE OF EACH SAMPLE IS
DETERMINED FROM TWO SNPS. THE TABLE CONSISTS OF NINE CELLS
WHERE EACH CELL REPRESENTS A UNIQUE GENOTYPE. THE LEFT
(BLACK) BAR IN EACH CELL REPRESENTS THE NUMBER OF CASE
SAMPLES WHILE THE RIGHT (WHITE) BAR REPRESENTS THE NUMBER OF
CONTROL SAMPLES. THE CELLS WITH GENOTYPES AaBb, aaBb, Aabb
AND aabb ARE LABELLED AS PREDISPOSING GENOTYPES WHILE THE
CELLS WITH GENOTYPES AABB, AaBB, aaBB, AABb AND AAbb ARE
LABELLED AS PROTECTIVE GENOTYPES.
from the number of testing folds with accuracy greater than
or equal to 50%. This single-tailed p-value is given by
p =
nf∑
i=na
(
nf
i
)(
1
2
)nf
(1)
where nf is the total number of cross-validation folds and na
is the number of cross-validation folds with testing accuracy
≥ 50% [9]. Among three criteria, prediction accuracy is
the main criterion for decision making while the other
criteria are only used as auxiliary measures. Cross-validation
consistency generally confirms that the high rank model can
be consistently identified regardless of how the samples are
divided for cross-validation. On the other hand, a sign test
p-value indicates the number of testing folds with acceptable
prediction accuracy and hence describes the usability of
the model in the classification task. In the situation where
two or more models with different number of markers are
equally good in terms of prediction accuracy, cross-validation
consistency and sign test p-value, the most parsimonious
model—the combination with the least number of markers—
will be the best model.
B. Haplotype Inference
With the availability of multiple SNPs from the same gene,
haplotypes can be inferred from given genotypes. Let ‘0’
and ‘1’ denote the major (common) and minor (rare) alleles
at a SNP location in a haplotype. A genotype can then be
represented by a string, which consists of three characters:
‘0’, ‘1’ and ‘2’. In the genotype string, ‘0’ denotes a
homozygous wide-type site, ‘1’ denotes a heterozygous
site and ‘2’ denotes a homozygous variant or homozygous
mutant site. A genotype with all homozygous sites or single
heterozygous site can always be phased into one pair of
haplotypes. On the other hand, a genotype with multiple
heterozygous sites can be phased into multiple haplotype
pairs. For example, genotype 0102 leads to haplotypes
0001 and 0101 while genotype 0112 leads to two pos-
sible haplotype pairs: 0001/0111 and 0011/0101. Many
algorithms exist for haplotype inference [15], [16], [17]. In
this paper, an expectation-maximisation algorithm [15] is the
chosen technique due to its simplicity and implementation
efficacy. Regardless of the inference technique employed, the
usual result from an inference algorithm covers haplotype
frequencies and possible haplotype phases of each genotype.
C. Haplotype Explanation Probability
In a genomic region with multiple heterozygous sites,
multiple pairs of haplotypes can be inferred from a given
genotype. The probability of a genotype to be phased into one
specific pair of haplotypes would depend on the frequencies
of haplotypes constituting the pairs [14]. This probability is
given by
wij =
fifj∑
(hk,hl)∈H
fkfl
(2)
where wij is the probability for haplotype pair ij, fi denotes
the frequency of the ith haplotype, hk is the kth haplotype
and H represents the set of haplotype explanations which
are compatible with the genotype of interest. For example,
genotype 0110 can be phased into two haplotype pairs:
0000/0110 (h1/h4) and 0010/0100 (h2/h3). If the
frequencies for haplotypes 0000, 0010, 0100 and 0110
are respectively 0.5, 0.2, 0.2 and 0.1, the probabilities for the
pairs 0000/0110 and 0010/0100 are 0.556 and 0.444.
Obviously, the probability of a genotype with all homozy-
gous sites or single heterozygous site to be phased into a pair
of haplotypes would be equal to one. In genetic interaction
studies where the number of genes or unlinked regions is
greater than one, the haplotype explanation probabilities from
all regions can be combined together. An overall contribution
by one sample to haplotype configuration (h1j , h2j , . . . , h
nu
j )
in a study with nu genes/unlinked regions is given by
c(h1
j
,h2
j
,...,h
nu
j
) = 2
nu∏
i=1
wijk
(1 + δijk)
2
(3)
where c(h1
j
,h2
j
,...,h
nu
j
) is the contribution value and δ is
defined as δjk = 1 for j = k and δjk = 0 for j 6= k. In the
previous example where haplotypes from only one region
are considered, ch1 = 0.556 , ch2 = 0.444, ch3 = 0.444
and ch4 = 0.556. Notice that the sum of contribution values
is equal to two; this reflects the fact that each genotype is
made up from two haplotypes. Becker et al. [14] use this
contribution value in the construction of a contingency table
where a χ2 test statistic is subsequently calculated. With
the use of a Monte Carlo simulation, an estimated p-value
is then obtained for the test statistic. Similar to the model
exploration strategy in MDR, the process of contingency
table construction and p-value calculation can also be cycled
Fig. 2
A VARHAP DECISION TABLE WHICH IS CONSTRUCTED FROM 1,200
CASE-CONTROL SAMPLES. HAPLOTYPES IN THE FIRST GENE ARE
OBTAINED FROM ONE SNP WHILE HAPLOTYPES IN THE SECOND GENE
ARE INFERRED FROM TWO SNPS. THE TABLE CONSISTS OF EIGHT
CELLS WHERE EACH CELL REPRESENTS A UNIQUE HAPLOTYPE
CONFIGURATION. THE LEFT (BLACK) BAR IN EACH CELL REPRESENTS
THE ACCUMULATIVE CONTRIBUTION FROM CASE SAMPLES WHILE THE
RIGHT (WHITE) BAR REPRESENTS THE ACCUMULATIVE CONTRIBUTION
FROM CONTROL SAMPLES. THE CELLS WITH HAPLOTYPE
CONFIGURATIONS (h1
2
, h2
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) AND (h1
1
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3
) ARE LABELLED AS
PROTECTIVE HAPLOTYPE CONFIGURATIONS.
through all or some of possible interaction models. The
model with appropriate candidate SNPs taken from possible
SNPs is the one with minimum p-value and is said to be the
best model for interaction explanation. This statistics-based
procedure can be found as an integral part of the FAMHAP
program [18].
III. VARHAP
VarHAP is proposed for case-control interaction studies.
Similar to MDR, the technique is also a classifier-based tech-
nique. However, instead of using a genotype data analysis as
a means to identify the best SNP combination, the decision
table for classification is constructed from the haplotype
contribution value described earlier. As a result, haplotypes
with different lengths must be inferred during the search for
the best model. The number of decision cells during the
consideration on haplotypes constructed from a specific set of
SNPs is governed by the total number of possible haplotype
configurations as illustrated in Figure 2. In brief, VarHAP
would maintain the ability to find the best SNP combination
while also be able to identify possible disease-predisposing
and protective haplotype configurations.
Since VarHAP is essentially a classification system, the
principal criterion for choosing the optimal SNP combination
TABLE I
DESCRIPTION OF TWO-LOCUS DISEASE MODELS. dij IS THE PENETRANCE OF A GENOTYPE CARRYING i DISEASE ALLELES AT LOCUS 1 AND j
DISEASE ALLELES AT LOCUS 2. p1 IS THE FREQUENCY OF THE DISEASE ALLELE AT LOCUS 1 WHILE p2 IS THE FREQUENCY OF THE DISEASE ALLELE
AT LOCUS 2. ψ = 2φ− φ2 .
Model d22 d21 d20 d12 d11 d10 d02 d01 d00 p1 p2 φ
Ep-1 φ φ 0 φ φ 0 0 0 0 0.210 0.210 0.707
Ep-2 φ φ 0 0 0 0 0 0 0 0.600 0.199 0.778
Ep-3 φ 0 0 0 0 0 0 0 0 0.577 0.577 0.900
Ep-4 φ φ 0 φ 0 0 φ 0 0 0.372 0.243 0.911
Ep-5 φ φ 0 φ 0 0 0 0 0 0.349 0.349 0.799
Ep-6 0 φ φ φ 0 0 φ 0 0 0.190 0.190 1.000
Het-1 ψ ψ φ ψ ψ φ φ φ 0 0.053 0.053 0.495
Het-2 ψ ψ φ φ φ 0 φ φ 0 0.279 0.040 0.660
Het-3 ψ φ φ φ 0 0 φ 0 0 0.194 0.194 1.000
S-1 φ φ φ φ φ φ φ φ 0 0.052 0.052 0.522
S-2 1 1 1 φ φ 0 φ φ 0 0.228 0.045 0.574
S-3 1 1 φ 1 φ 0 φ 0 0 0.194 0.194 0.512
model is still the prediction accuracy. However, with the
use of haplotype contribution value as a means for decision
rule construction, an additional model selection criterion
that exploits the nature of haplotype can be formulated.
This criterion can be referred to as haplotype propagation
capability. Basically, if a haplotype constructed from a spe-
cific set of SNPs is related to disease susceptibility status,
haplotypes constructed from a SNP set which is a superset of
the previously specified SNPs should also predict the same
relationship. This implies that predisposing and protective
haplotypes in a low-order model must be able to propagate
into haplotypes in high-order models. For example, consider
a single-gene problem with four possible SNPs: X1, X2,
X3 and X4. If haplotypes in the model with SNPs (X2,
X4) are related to disease susceptibility, haplotypes in the
models with SNPs (X1, X2, X4), (X2, X3, X4) and
(X1, X2, X3, X4) should produce the same result. The
haplotype propagation capability, which is a dichotomous
criterion, can be determined from the evidence that the sign
test p-value and the prediction accuracy can be maintained
throughout the process of model order increment. Again,
in the situation where two or more models with different
number of SNPs are equally good in terms of both prediction
accuracy and haplotype propagation capability, the most
parsimonious model will be the best model.
IV. DATA SETS
The performance of the proposed VarHAP technique is
evaluated through benchmark trials. 12 simulated data sets,
which represent various gene-gene interaction phenomena
including epistasis and heterogeneity, are considered [14],
[19]. Each data set contains 600 case samples and 600 control
samples. Each sample consists of 10 total SNPs from two
genes where five SNPs exist in each gene. All SNPs in con-
trol samples are in Hardy-Weinberg equilibrium [20]. Only
one SNP from each gene is interacted with one another. The
two-locus interaction models are illustrated in Table I. The
epistatic models Ep-1–Ep-6 and the heterogeneity models
Het-1–Het-3 have been discussed by Neuman and Rice [21],
who also provide examples of diseases for which these
models may be applicable. The heterogeneity models S-1
and S-2 and the epistatic model S-3 have been investigated
by Schork et al. [22]. From Table I, if the frequency of
the disease allele at a locus is greater than 0.5, the major
allele is the disease allele. Otherwise, the minor allele is
the disease allele. These interaction models describe disease
susceptibility status in terms of penetrance. Penetrance of
a genotype with a specific number of disease alleles is
the probability that a subject with this genotype has the
disease. The test data sets are simulated by a genomeSIM
package [23] with the default setting. As a result, it is also
possible to vary the LD pattern among SNPs in the same
gene. This leads to two main case studies that need to
be explored: strong LD and weak LD cases. In the strong
LD case, the susceptibility-causative SNP in each gene and
its two adjacent SNPs are in linkage disequilibrium where
Lewontin’s D′ value [24] is in the range of 0.80–0.95. In
contrast, the Lewontin’s D′ value for each pairwise LD
measurement between susceptibility-causative SNP and its
adjacent SNPs is in the range of 0.50–0.60 in the weak
LD case. In the strong LD case, an interaction detection
technique should be able to identify both the actual two-
locus model that directly leads to disease susceptibility and
other alternative models which consist of SNPs in strong LD
patterns. The ability to detect these other models is important.
This is because it is not always straightforward to identify
SNPs which are responsible for disease susceptibility in real
case-control interaction studies. In contrast, an interaction
detection technique should narrow the search to the original
two-locus model in weak LD case since it is the only usable
model.
TABLE II
MDR, VARHAP AND FAMHAP RESULTS FROM THE WEAK LD CASE STUDY. 10-FOLD CROSS-VALIDATION IS USED IN MDR AND VARHAP. THE
PREDICTION ACCURACY IS OBTAINED FOR THE IDENTIFIED PRINCIPAL INTERACTION MODEL. ESTIMATED p-VALUES IN FAMHAP RESULTS ARE
EQUAL TO ZERO WHILE SIGN TEST p-VALUES IN MDR AND VARHAP RESULTS ARE LESS THAN 0.001 IN ALL TWO-LOCUS PROBLEMS. THE
TECHNIQUE IS SAID TO BE ABLE TO IDENTIFY THE CORRECT GENE-GENE INTERACTION MODEL IF THE REPORTED PRINCIPAL MODEL CONTAINS BOTH
SNPS WHICH ARE DIRECTLY PARTICIPATED IN THE INTERACTION MODEL. ALTERNATIVE MODELS ARE MODELS WHICH CONTAIN AT LEAST TWO
SNPS WHERE EACH SNP MUST BE EITHER A SNP FROM THE TWO-LOCUS MODEL OR A SNP WHICH IS IN LINKAGE DISEQUILIBRIUM WITH ONE OF
THE SNPS FROM THE MODEL. THE NUMBER IN EACH BRACKET DENOTES THE ORDER OF THE IDENTIFIED MODEL (THE NUMBER OF SNPS IN THE
MODEL).
Two- MDR VarHAP Correct Alternative
Locus Prediction Prediction Model Model
Model Accuracy Accuracy Identification Identification
(%) (%) Technique Technique
Ep-1 98.00 73.92 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
Ep-2 98.58 78.39 MDR(2), VarHAP(4), FAMHAP(2) FAMHAP(2)
Ep-3 99.50 87.50 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
Ep-4 99.25 78.96 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
Ep-5 98.42 75.19 MDR(2), VarHAP(3), FAMHAP(2) FAMHAP(2)
Ep-6 100.00 85.10 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
Het-1 93.75 73.29 MDR(2), VarHAP(2), FAMHAP(2)
Het-2 97.33 78.40 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
Het-3 100.00 84.40 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
S-1 94.00 72.98 MDR(2), VarHAP(2), FAMHAP(2)
S-2 97.58 79.81 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
S-3 96.75 79.15 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
V. RESULTS AND DISCUSSIONS
VarHAP is benchmarked against MDR and FAMHAP.
Since the test data contains 10 SNPs, all three techniques
have to explore 210 − 1 = 1, 023 possible SNP com-
bination models. An initial investigation reveals that with
the use of minimum p-value as the sole model selection
criterion, FAMHAP reports a large number of models with
the estimated p-value equals to zero. As a result, haplotype
propagation capability is also implemented as an additional
model selection criterion. Further, the parsimony criterion is
also utilised when there is a tie between multiple models with
different number of SNPs. The results from all three tech-
niques in weak and strong LD case studies are summarised
in Tables II and III, respectively.
The prediction accuracy of MDR is higher than that of
VarHAP in both case studies. This is because VarHAP uses
contribution values which are obtained from inferred hap-
lotypes instead of inferred diplotypes—pairs of haplotypes
that together describe correct phases of given genotypes—
to create decision rules. Consider a situation where disease
susceptibility can be determined from a single SNP where
the predisposing genotype is the homozygous variant. In
other words, the disease susceptibility can be described by
a recessive genetic model. MDR can easily classify the
heterozygous and homozygous wide-type genotypes as pro-
tective genotypes. However, VarHAP would only correctly
classify both homozygous genotypes since each genotype
is made up from two copies of the same haplotype: two
major alleles for the homozygous wide-type and two minor
alleles for the homozygous variant. VarHAP would partially
misclassify samples with heterozygous genotype. This is
because VarHAP identifies the major allele as the protective
allele and the minor allele as the predisposing allele. In order
to increase the prediction accuracy of VarHAP, it may be
necessary to construct decision tables from diplotype infor-
mation instead of haplotype contribution values. Nonetheless,
this will also rapidly increase the dimensions of decision
tables in VarHAP.
In the weak LD case study, both MDR and VarHAP are
able to identify correct sets of SNPs that lead to disease
susceptibility. On the other hand, FAMHAP reports both
actual and alternative interaction models. This is undesirable
since it would not be possible to further explain disease
susceptibility from multiple candidate models in the absence
of strong linkage disequilibrium among SNPs. In other
words, FAMHAP is quite sensitive in this situation. Further
analysis reveals that MDR is marginally better than VarHAP
in two epistasis problems: Ep-2 and Ep-5. MDR correctly
identifies models which contain two SNPs while the models
located by VarHAP contain a few extra SNPs. Nonetheless,
these two models identified by VarHAP are still useful to
susceptibility explanation.
All three techniques are able to locate correct interaction
models in the strong LD case study. However, only FAMHAP
and VarHAP are capable of identifying alternative models.
Since MDR suggests one candidate model for each fixed-
TABLE III
MDR, VARHAP AND FAMHAP RESULTS FROM THE STRONG LD CASE STUDY. THE EXPLANATION FOR HOW THE RESULTS ARE OBTAINED AND
DISPLAYED IS THE SAME AS THAT GIVEN IN TABLE II.
Two- MDR VarHAP Correct Alternative
Locus Prediction Prediction Model Model
Model Accuracy Accuracy Identification Identification
(%) (%) Technique Technique
Ep-1 98.00 73.92 MDR(2), VarHAP(2), FAMHAP(2) VarHAP(2),
FAMHAP(2)
Ep-2 98.58 77.02 MDR(2), VarHAP(4), FAMHAP(2) VarHAP(4),
FAMHAP(2)
Ep-3 99.50 87.50 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
Ep-4 99.25 78.96 MDR(2), VarHAP(2), FAMHAP(2) VarHAP(2),
FAMHAP(2)
Ep-5 98.42 75.87 MDR(2), VarHAP(3), FAMHAP(2) VarHAP(3),
FAMHAP(2)
Ep-6 100.00 85.10 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
Het-1 93.75 75.41 MDR(2), VarHAP(3), FAMHAP(2) VarHAP(3),
FAMHAP(2)
Het-2 97.33 78.40 MDR(2), VarHAP(2), FAMHAP(2) VarHAP(2),
FAMHAP(2)
Het-3 100.00 84.40 MDR(2), VarHAP(2), FAMHAP(2) FAMHAP(2)
S-1 94.00 72.98 MDR(2), VarHAP(2), FAMHAP(2) VarHAP(2),
FAMHAP(2)
S-2 97.58 79.81 MDR(2), VarHAP(2), FAMHAP(2) VarHAP(2),
FAMHAP(2)
S-3 96.75 79.15 MDR(2), VarHAP(2), FAMHAP(2) VarHAP(2),
FAMHAP(2)
number SNP set, it would not be possible for MDR to
produce any alternative models. Recall that these alternative
models are equally important since SNPs in the principal
two-locus interaction model and SNPs from an alternative
model are in strong linkage disequilibrium. This implies
that disease susceptibility can be explained using either the
original interaction model or the alternative models. This
disadvantage in MDR can be overcome if the cross-validation
consistency criterion can be replaced by other decision
criteria. In this case study, FAMHAP is marginally better
than VarHAP in terms of alternative model identification in
three epistasis and heterogeneity problems: Ep-3, Ep-6 and
Het-3. This means that FAMHAP is at its best when SNPs
are in strong linkage disequilibrium. Nonetheless, the overall
results from both case studies suggest that VarHAP is the best
technique. This is concluded from the fact that VarHAP does
not report ambiguous results in weak LD case study while
is also capable of producing alternative models in strong
LD case study. This is crucial because it is impossible to
know beforehand whether susceptibility-causative SNPs are
in weak or strong linkage disequilibrium with other SNPs
in real case-control interaction studies. In other words, a
technique that performs satisfactorily in both weak and strong
LD cases would have an advantage over a technique that
functions well in only one scenario.
VI. CONCLUSIONS
In this paper, a non-parametric pattern recogni-
tion/classification technique for case-control gene-gene
interaction studies is presented. Instead of using direct
genotype inputs in classification, inferred haplotypes,
which are obtained through an expectation-maximisation
algorithm [15], are used as inputs. Each case/control
sample contributes values derived from inferred haplotypes
to decision tables which are constructed and tested for
all possible gene-gene interaction models. The technique
primarily uses prediction accuracy obtained from k-fold
cross-validation as a means for identifying candidate
SNPs which are responsible for disease susceptibility. The
technique also employs haplotype propagation capability as
an additional criterion. If the selection procedure ends in
a tie between two or more models with different number
of SNPs, the most parsimonious model is then reported
as the interaction model. Since haplotypes with different
length must be constructed during model identification, the
proposed technique can be referred to as a variable-length
haplotype construction for gene-gene interaction (VarHAP)
technique. VarHAP has been benchmarked against two
interaction model detection programs namely MDR [9]
and FAMHAP [14], [18] in 12 two-locus epistasis and
heterogeneity problems [14], [19]. The results reveal
that FAMHAP reports multiple ambiguous models in the
presence of weak linkage disequilibrium among input
SNPs while MDR is not suitable for alternative interaction
model identification when input SNPs are in strong linkage
disequilibrium. In contrast, VarHAP emerges as the most
suitable technique in both situations involving weak and
strong linkage disequilibrium. Suggestions for further
improvement of MDR and VarHAP are also included.
SUPPLEMENTARY INFORMATION
VarHAP, which is implemented in Java, and the simulated
data sets used in the article are available upon request
(email: nchl@kmutnb.ac.th). In addition to the use
of the genomeSIM package [23], the data sets can also
be generated by a SNaP package [25]. Readers might also
be interested in applying the techniques discussed in this
article to examples of case-control data sets, which are
publicly available from the Wellcome Trust Case Control
Consortium [26].
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